中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

21 records (took 0.016 seconds)

    DENDRITIC CELL BASED VACCINES
    4.
    发明申请
    DENDRITIC CELL BASED VACCINES 审中-公开
    基于细胞的细胞疫苗

    公开(公告)号：WO2007050102A3

    公开(公告)日：2007-10-18

    申请号：PCT/US2005042996

    申请日：2005-11-29

    Applicant: UNIV NORTH CAROLINA ,  SERODY JONATHAN ,  DAVIS NANCY L ,  JOHNSTON ROBERT E ,  MORAN TIMOTHY

    Inventor： SERODY JONATHAN ,  DAVIS NANCY L ,  JOHNSTON ROBERT E ,  MORAN TIMOTHY

    IPC: A61K39/12 ,  A61K39/193

    CPC classification number: A61K39/00 ,  A61K2039/5256 ,  C12N15/86 ,  C12N2770/36143

    Abstract: The present invention provides an isolated human dendritic cell comprising a recombinant alphavirus vector RNA that comprises a heterologous nucleic acid sequence encoding an antigen. In particular embodiments, the alphavirus vector RNA is a Venezuelan Equine Encephalitis virus (VEE) vector RNA. In other embodiments, the antigen is an infectious disease antigen or a cancer antigen. Also provided are compositions and pharmaceutical formulations comprising the inventive dendritic cells, as well as methods of inducing an immune response against an infectious agent or a cancer and methods of treating an infectious disease or cancer.

    Abstract translation: 本发明提供了包含重组甲病毒载体RNA的分离的人树状细胞，其包含编码抗原的异源核酸序列。 在具体实施方案中，甲病毒载体RNA是委内瑞兰马脑炎病毒（VEE）载体RNA。 在其它实施方案中，抗原是感染性疾病抗原或癌抗原。 还提供了包含本发明的树突细胞的组合物和药物制剂，以及诱导针对感染剂或癌症的免疫应答的方法以及治疗感染性疾病或癌症的方法。

    DENDRITIC CELL BASED VACCINES
    5.
    发明申请
    DENDRITIC CELL BASED VACCINES 审中-公开
    基于树突状细胞的疫苗

    公开(公告)号：WO2007050102A2

    公开(公告)日：2007-05-03

    申请号：PCT/US2005/042996

    申请日：2005-11-29

    Applicant: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL ,  SERODY, Jonathan ,  DAVIS, Nancy, L. ,  JOHNSTON, Robert, E. ,  MORAN, Timothy

    Inventor： SERODY, Jonathan ,  DAVIS, Nancy, L. ,  JOHNSTON, Robert, E. ,  MORAN, Timothy

    IPC: A61K48/00

    CPC classification number: A61K39/00 ,  A61K2039/5256 ,  C12N15/86 ,  C12N2770/36143

    Abstract: The present invention provides an isolated human dendritic cell comprising a recombinant alphavirus vector RNA that comprises a heterologous nucleic acid sequence encoding an antigen. In particular embodiments, the alphavirus vector RNA is a Venezuelan Equine Encephalitis virus (VEE) vector RNA. In other embodiments, the antigen is an infectious disease antigen or a cancer antigen. Also provided are compositions and pharmaceutical formulations comprising the inventive dendritic cells, as well as methods of inducing an immune response against an infectious agent or a cancer and methods of treating an infectious disease or cancer.

    Abstract translation: 本发明提供了分离的人树突细胞，其包含含有编码抗原的异源核酸序列的重组甲病毒载体RNA。 在具体的实施方案中，甲病毒载体RNA是委内瑞拉马脑炎病毒（VEE）载体RNA。 在其他实施方案中，抗原是传染病抗原或癌抗原。 还提供了包含本发明的树状细胞的组合物和药物制剂，以及诱导针对感染剂或癌症的免疫应答的方法以及治疗感染性疾病或癌症的方法。

    IMPROVED ALPHAVIRUS VECTORS HAVING ATTENUATED VIRION STRUCTURAL PROTEINS
    7.
    发明申请
    IMPROVED ALPHAVIRUS VECTORS HAVING ATTENUATED VIRION STRUCTURAL PROTEINS 审中-公开
    具有衰减病毒结构蛋白质的改良型ALVHAVIRUS载体

    公开(公告)号：WO2004000872A2

    公开(公告)日：2003-12-31

    申请号：PCT/US2003/019626

    申请日：2003-06-20

    Applicant: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL ,  ALPHAVAX, INC. ,  DAVIS, Nancy ,  WEST, Edna ,  JOHNSTON, Robert, E. ,  SMITH, Jonathan

    Inventor： DAVIS, Nancy ,  WEST, Edna ,  JOHNSTON, Robert, E. ,  SMITH, Jonathan

    IPC: C07K

    CPC classification number: A61K39/145 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/54 ,  C12N7/00 ,  C12N2740/16222 ,  C12N2740/16234 ,  C12N2760/16034 ,  C12N2770/36143 ,  C12N2770/36161

    Abstract: The present invention provides immunogenic compositions and methods that may be used to administer safer (i.e., attenuated) alphavirus vectors (such as alphavirus vectors comprising a VEE virion shell) that retain improved immunogenicity as compared with other attenuated alphaviruses (e.g., the VEE 3014 mutant, described below). In particular embodiments of the invention, the alphavirus vector comprises VEE structural proteins comprising an attenuating mutation in the E1 glycoprotein. In other particular embodiments, the attenuating mutation is in the fusogenic region of the E1 glycoprotein. The present invention enables administration of lower dosages of a safer (i.e., attenuated) virus and, thus, can further reduce manufacturing costs. The present inventors have found that immunogenicity of alphavirus vectors may be influenced by a number of factors including species, site and route of administration.

    Abstract translation: 本发明提供免疫原性组合物和方法，其可用于与其他减毒的甲病毒（例如，VEE 3014突变体）相比，其保持更高（即减毒）的甲病毒载体（例如包含VEE病毒粒子的甲病毒载体），其保持改善的免疫原性 ， 如下面所描述的）。 在本发明的具体实施方案中，甲病毒载体包含包含E1糖蛋白中的减毒突变的VEE结构蛋白。 在其它具体实施方案中，减毒突变位于E1糖蛋白的融合区。 本发明使得能够施用较低剂量的更安全（即，减毒）的病毒，因此可以进一步降低制造成本。 本发明人已经发现甲病毒载体的免疫原性可能受许多因素的影响，包括物种，部位和给药途径。

    DENDRITIC CELL BASED VACCINES
    9.
    发明申请
    DENDRITIC CELL BASED VACCINES 审中-公开
    基于树突状细胞的疫苗

    公开(公告)号：WO2007050102A9

    公开(公告)日：2007-07-05

    申请号：PCT/US2005042996

    申请日：2005-11-29

    Applicant: UNIV NORTH CAROLINA ,  SERODY JONATHAN ,  DAVIS NANCY L ,  JOHNSTON ROBERT E ,  MORAN TIMOTHY

    Inventor： SERODY JONATHAN ,  DAVIS NANCY L ,  JOHNSTON ROBERT E ,  MORAN TIMOTHY

    IPC: A61K48/00

    CPC classification number: A61K39/00 ,  A61K2039/5256 ,  C12N15/86 ,  C12N2770/36143

    Abstract: The present invention provides an isolated human dendritic cell comprising a recombinant alphavirus vector RNA that comprises a heterologous nucleic acid sequence encoding an antigen. In particular embodiments, the alphavirus vector RNA is a Venezuelan Equine Encephalitis virus (VEE) vector RNA. In other embodiments, the antigen is an infectious disease antigen or a cancer antigen. Also provided are compositions and pharmaceutical formulations comprising the inventive dendritic cells, as well as methods of inducing an immune response against an infectious agent or a cancer and methods of treating an infectious disease or cancer.

    Abstract translation: 本发明提供了包含重组甲病毒载体RNA的分离的人树突状细胞，所述重组甲病毒载体RNA包含编码抗原的异源核酸序列。 在具体的实施方案中，甲病毒载体RNA是委内瑞拉马脑炎病毒（VEE）载体RNA。 在其他实施方案中，抗原是传染病抗原或癌抗原。 还提供了包含本发明的树状细胞的组合物和药物制剂，以及诱导针对感染剂或癌症的免疫应答的方法以及治疗感染性疾病或癌症的方法。

    IMPROVED METHODS FOR ACHIEVING EXPRESSION FROM ALPHAVIRUS VECTORS
    10.
    发明申请
    IMPROVED METHODS FOR ACHIEVING EXPRESSION FROM ALPHAVIRUS VECTORS 审中-公开
    用于从ALPHAVIRUS VECTORS中获得表达的改进方法

    公开(公告)号：WO2003083065A2

    公开(公告)日：2003-10-09

    申请号：PCT/US2003/009121

    申请日：2003-03-25

    Applicant: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL ,  RYMAN, Kate, D. ,  KLIMSTRA, William, B. ,  JOHNSTON, Robert, E. ,  WHITE, Laura, J. ,  WANG, Jiagang

    Inventor： RYMAN, Kate, D. ,  KLIMSTRA, William, B. ,  JOHNSTON, Robert, E. ,  WHITE, Laura, J. ,  WANG, Jiagang

    IPC: C12N

    CPC classification number: C12N7/00 ,  C12N2770/36161

    Abstract: The present invention provides methods and reagents for enhancing alphavirus replication and gene expression in target cells by manipulating the PKR and/or IFN induced antiviral pathways present in the cell. The methods may also be practiced to expand alphavirus tropism to cells that are typically non-permissive, or only poorly so, for alphavirus replication and infection. The methods may be practiced in vitro, ex vivo or in vivo, for example, for the purposes of producing an alphavirus vector stock or a protein of interest in vitro, or for achieving immunogenic or therapeutic effects in a subject in vivo. Also provided are reagents (helper cells, nucleic acid constructs, helper sequences, alphavirus vectors, and the like) for practicing the methods of the invention.

    Abstract translation: 本发明提供了通过操纵存在于细胞中的PKR和/或IFN诱导的抗病毒途径来增强靶细胞中甲病毒病毒复制和基因表达的方法和试剂。 也可以实施这些方法以将甲病毒向性扩增到通常不允许的细胞，或者仅仅是差的甲病毒复制和感染的细胞。 所述方法可以在体外，离体或体内实施，例如用于在体外产生感兴趣的甲病毒载体原料或蛋白质的目的，或用于在体内实现受试者的免疫原性或治疗效果。 还提供了用于实施本发明方法的试剂（辅助细胞，核酸构建体，辅助序列，甲病毒载体等）。

Patent Agency Ranking